From: Drugging the unfolded protein response in acute leukemias
Compound | Molecular target | Disease | Stage of clinical development | References |
---|---|---|---|---|
STF-083010 | IRE-1 | Multiple myeloma | Preclinical | Papandreou et al. [99] |
ALL | Kharabi Masouleh et al. [87] | |||
CLL | Kriss et al. [116] | |||
A106 | IRE-1 | CLL | Preclinical | Kriss et al. [116] |
ALL | Kharabi Masouleh et al. [87] | |||
MKC-3946 | IRE-1 | Multiple myeloma | Preclinical | Volkmann et al. [100] |
Mimura et al. [101] | ||||
4μ8c | IRE-1 | Multiple myeloma | Preclinical | Cross et al. [102] |
GSK2606414 | PERK | Multiple myeloma | Preclinical | Axten et al. [98] |
GSK2656157 | Pancreatic cancer | |||
Epigallocatechin gallate (EGCG) | GRP78 | ALL | Preclinical | Uckun et al. [111] |
PAT-SM6 | GRP78 | Melanoma | Preclinical | Rosenez et al. [113] |
Multiple myeloma | Rasche et al. [114] | |||
Pep42 | GRP78 | ALL | Preclinical | Uckun et al. [111] |